Viral Gastroenteritis Market Size & Share to Exceed USD 10.2 Billion by 2034, at CAGR of 4.6%. “Conquering the Waves: Breakthroughs in Viral Gastroenteritis Market Surge Toward a Healthier Tomorrow!” – PMI Leads the Way

Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) — “According to the recent research study, the Viral Gastroenteritis Market size was valued at about USD 6.8 Billion in 2024 and expected to grow at CAGR of 4.6% to extend a value of USD 10.2 Billion by 2034.”

What is Viral Gastroenteritis?

Advertisement

  • Market Overview:

Viral gastroenteritis, often referred to as the stomach flu, is an inflammation of the stomach and intestines caused by a viral infection. The most common viruses associated with gastroenteritis include norovirus, rotavirus, adenovirus, and astrovirus. This condition is highly contagious and spreads through the consumption of contaminated food or water, contact with infected individuals, or touching surfaces contaminated with the virus.
Symptoms of viral gastroenteritis typically include diarrhea, vomiting, abdominal cramps, nausea, fever, and muscle aches. The illness is usually self-limiting and resolves on its own within a few days. However, it can lead to dehydration, especially in vulnerable populations such as young children and the elderly.
Preventive measures include practicing good hygiene, such as frequent handwashing, avoiding contaminated food and water, and maintaining a clean environment. In severe cases, medical attention may be required to manage dehydration and alleviate symptoms.

Viral Gastroenteritis Market

  • Market Dynamics:

Driving Factors:

  • Viral gastroenteritis is highly contagious, leading to frequent outbreaks in communities, healthcare settings, and other environments. The prevalence of the condition drives the demand for effective treatments and preventive measures.
  • Increased global travel and interconnectedness contribute to the spread of viral gastroenteritis. People moving across borders can inadvertently carry the viruses to new regions, creating a demand for solutions to manage and prevent outbreaks.
  • Ongoing research and development of vaccines against common viruses causing gastroenteritis, such as norovirus and rotavirus, are significant drivers. Advances in vaccine technology can lead to improved prevention strategies and reduce the overall burden of the disease.
  • Improvements in diagnostic technologies allow for quicker and more accurate identification of viral gastroenteritis cases. This facilitates timely intervention and management, contributing to market growth.
  • Changes in lifestyle, dietary habits, and increased urbanization can impact the prevalence of viral gastroenteritis. These factors may lead to a higher demand for healthcare solutions to address the changing disease landscape.
  • Collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations contribute to advancements in viral gastroenteritis treatment and prevention. Such partnerships can accelerate the development and availability of new therapies.

Restrain Factors:

  • Higher mutation rates.
  • Lack of specific antiviral treatment.
  • Limited awareness & education.
  • Vaccine hesitancy.
  • Diagnostic challenges.
  • Global health security risks.

Get Access to Free Sample Research Report with Latest Industry Insights:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4694

*Note: PMI Sample Report includes,

  • Overview & introduction of market study
  • Revenue and CAGR of market 
  • Drivers & Restrains factors of market 
  • Major key players in market 
  • Regional analysis of the market with a detailed graph
  • Detailed segmentation in tabular form of market 
  • Recent development/news of market 
  • Opportunities & Challenges of Market 

Report scope:

Attribute Details
Market Size 2024 US$ 6.8 billion
Projected Market Size 2034 US$ 10.2 billion
CAGR Growth Rate 4.6 %
Market Segmentation By Type -Rotavirus and Norovirus

By Drugs –Antacids, Antibiotics, Laxatives Anti mobility Agents

By Diagnosis- Rapid Stool Test and Physical Examination

By End-Use- Hospital, Diagnostic Centers, Clinics and Others

Regional scope North America – U.S., Canada

Europe – UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific – Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America – Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage Revenue forecast, company share, competitive landscape, growth factors, and trends

Top Leading Players in Viral Gastroenteritis Market:

  • Abbott
  • Valeant Pharmaceuticals International Inc.
  • Janssen Global Services, LLC.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline Plc.
  • Bayer AG
  • AstraZeneca
  • Sanofi

Download PDF Brochure:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/4694

Emerging Trends and Opportunities in Viral Gastroenteritis Market:

  • The development of more rapid, accurate, and cost-effective diagnostic technologies is enhancing the early detection of viral gastroenteritis. Point-of-care testing and molecular diagnostics contribute to quicker and more precise identification of viral strains.
  • The increasing adoption of telemedicine allows healthcare providers to remotely monitor and manage patients with viral gastroenteritis. This trend offers convenience for both patients and healthcare professionals, especially in the context of managing mild cases and follow-up care.
  • Ongoing research and development efforts are focused on creating effective vaccines against various viruses causing gastroenteritis. Advances in vaccine technology and increased investment in preventive measures present opportunities for breakthroughs in disease prevention.
  • Increasing public health awareness campaigns regarding hygiene, sanitation, and vaccination play a crucial role in preventing the spread of viral gastroenteritis. Governments and healthcare organizations are likely to invest in educational initiatives to empower individuals and communities.
  • Advances in biotechnology, including the use of recombinant DNA technology, are contributing to the development of novel therapies and vaccines for viral gastroenteritis. These biotechnological innovations may offer more targeted and efficient treatment options.
  • The concept of personalized medicine is gaining traction, and tailoring treatments based on individual patient characteristics and viral strain variations may become more common in the management of viral gastroenteritis.

Challenges of Viral Gastroenteritis Market:

  • The absence of targeted antiviral treatments for many gastroenteritis viruses poses a significant challenge. Treatment mainly focuses on supportive care, and developing specific antiviral medications remains a complex task due to the diversity and mutability of these viruses.
  • While vaccines are crucial for preventing viral gastroenteritis, challenges such as high mutation rates in certain viruses, the need for broad-spectrum protection, and addressing vaccine hesitancy pose obstacles to successful vaccine development and widespread adoption.
  • Overcoming vaccine hesitancy and improving public education about the importance of vaccination and hygiene practices are ongoing challenges. Misinformation and concerns about vaccine safety can hinder efforts to achieve high vaccination rates.
  • Environmental conditions, such as poor sanitation and contaminated water sources, contribute to the persistence of viral gastroenteritis. Addressing these environmental factors requires coordinated efforts and investments in infrastructure, especially in developing regions.
  • Inadequate surveillance systems and underreporting of cases can impede the timely identification of outbreaks and hinder effective response measures. Strengthening disease surveillance is crucial for managing and preventing viral gastroenteritis.

Detailed Segmentation:

Viral Gastroenteritis Market, By Type, 2024 – 2034, (US$ Bn)

    • Rotavirus
    • Norovirus

Viral Gastroenteritis Market, By Drugs, 2024 – 2034, (US$ Bn)

    • Antacids
    • Antibiotics
    • Laxatives
    • Antimobility agents

Viral Gastroenteritis Market, By Diagnosis, 2024 – 2034, (US$ Bn)

    • Rapid Stool tests
    • Physical examination

Viral Gastroenteritis Market, By End-User, 2024 – 2034, (US$ Bn)

    • Hospitals
    • Diagnostic centers
    • Clinics
    • Others

Viral Gastroenteritis Market, By Region, 2024 – 2034, (US$ Bn)

    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East

Key highlights of the Viral Gastroenteritis Market:

  • Viral gastroenteritis is known for its high contagiousness, leading to frequent outbreaks in various settings such as households, healthcare facilities, and community environments.
  • Viral gastroenteritis has a global impact, affecting populations in both developed and developing countries. The transmission is often facilitated by contaminated food, water, or contact with infected individuals.
  • Viral gastroenteritis has a global impact, affecting populations in both developed and developing countries. The transmission is often facilitated by contaminated food, water, or contact with infected individuals.
  • Treatment for viral gastroenteritis is primarily supportive, focusing on relieving symptoms and preventing dehydration. In severe cases, hospitalization and intravenous fluids may be necessary.
  • Governments, healthcare organizations, and international bodies actively promote public health awareness campaigns to educate the public about the importance of hygiene, vaccination, and other preventive measures.
  • Collaborations between pharmaceutical companies, research institutions, and healthcare organizations are driving innovation in the field. These partnerships aim to accelerate the development of effective therapies and preventive measures.
  • North America is expected to lead the market in the upcoming forecast era. This is mainly attributed because of the increasing prevalence of viral gastroenteritis in the U.S.

Any query or customization before buying:          

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/4694

Explore More Insights:

Blog: www.prophecyjournals.com

Follow us on:

LinkedIn | Twitter | Facebook |YouTube


Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.